Kairos Pharma, LTD. has made significant changes to its financial strategy by amending its equity line of credit agreement with Helena Global Investment Opportunities I Ltd. This decision, disclosed in a recent filing, is crucial for the company as it seeks to enhance its funding capabilities.

On November 3, 2026, Kairos Pharma announced the amendments to its Purchase Agreement with Helena, originally established on November 12, 2024. The latest changes include an extension of the option to utilize the equity line of credit (ELOC) for an additional year, now valid until December 31, 2028. This extension is expected to provide Kairos with greater financial flexibility as it advances its product development initiatives.

Background

Kairos Pharma, LTD. operates within the pharmaceutical preparations sector, classified under SIC code 2834. The company is publicly traded under the ticker symbol KAPA on the NYSE American exchange. As an emerging growth company, Kairos focuses on developing innovative pharmaceutical products.

What the Filing Says

The SEC filing details the amendments made to the Purchase Agreement. The first amendment, executed on February 4, 2026, adjusted the purchase price to 97% of the average daily volume-weighted average price (VWAP) during the pricing period. The second amendment, dated October 26, 2026, shortened the pricing period from three trading days to one trading day. The third amendment, which is the most recent, extends the ELOC option for an additional year.

Impact

This development may positively affect Kairos Pharma’s ability to secure necessary funding for ongoing and future projects. By extending the ELOC, the company can better manage its cash flow and invest in research and development efforts. This move may also influence other companies in the pharmaceutical preparations sector as they navigate similar funding challenges.

What's Next

The filing does not specify what happens next beyond the amendments made to the Purchase Agreement.

For further details, the complete filing can be accessed through the SEC's website under accession number 0001493152-26-049744.